BEXAGLIFLOZIN - Generic Drug Details

✉ Email this page to a colleague

What are the generic drug sources for bexagliflozin and what is the scope of patent protection?

Bexagliflozin is the generic ingredient in one branded drug marketed by Theracosbio and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Bexagliflozin has seventy-one patent family members in thirty-two countries.

Two suppliers are listed for this compound.

Summary for BEXAGLIFLOZIN

International Patents:	71
US Patents:	6
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	37
Clinical Trials:	16
Patent Applications:	116
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BEXAGLIFLOZIN
What excipients (inactive ingredients) are in BEXAGLIFLOZIN?	BEXAGLIFLOZIN excipients list
DailyMed Link:	BEXAGLIFLOZIN at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for BEXAGLIFLOZIN

Generic Entry Date for BEXAGLIFLOZIN^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: NEW CHEMICAL ENTITY Dosage: TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for BEXAGLIFLOZIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Theracos	Phase 2/Phase 3
Theracos	Phase 1
Theracos	Phase 3

See all BEXAGLIFLOZIN clinical trials

Pharmacology for BEXAGLIFLOZIN

Drug Class	Sodium-Glucose Cotransporter 2 Inhibitor
Mechanism of Action	Sodium-Glucose Transporter 2 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for BEXAGLIFLOZIN

A10BK	Sodium-glucose co-transporter 2 (SGLT2) inhibitors
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

US Patents and Regulatory Information for BEXAGLIFLOZIN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Theracosbio	BRENZAVVY	bexagliflozin	TABLET;ORAL	214373-001	Jan 20, 2023		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y		⤷ Sign Up
Theracosbio	BRENZAVVY	bexagliflozin	TABLET;ORAL	214373-001	Jan 20, 2023		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Theracosbio	BRENZAVVY	bexagliflozin	TABLET;ORAL	214373-001	Jan 20, 2023		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y		⤷ Sign Up
Theracosbio	BRENZAVVY	bexagliflozin	TABLET;ORAL	214373-001	Jan 20, 2023		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y		⤷ Sign Up
Theracosbio	BRENZAVVY	bexagliflozin	TABLET;ORAL	214373-001	Jan 20, 2023		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Theracosbio	BRENZAVVY	bexagliflozin	TABLET;ORAL	214373-001	Jan 20, 2023		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y		⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for BEXAGLIFLOZIN

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Russian Federation	2497526	ПРОИЗВОДНЫЕ БЕНЗИЛБЕНЗОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ (BENZYL BENZENE DERIVATIVES AND METHODS FOR USING THEM)	⤷ Sign Up
Australia	2011264220	Crystalline form of benzylbenzene SGLT2 inhibitor	⤷ Sign Up
Russian Federation	2569491	КРИСТАЛЛИЧЕСКАЯ ФОРМА БЕНЗИЛ-БЕНЗОЛЬНОГО ИНГИБИТОРА SGLT (CRYSTALLINE FORM OF BENZYL-BENZENE SGLT INHIBITOR)	⤷ Sign Up
World Intellectual Property Organization (WIPO)	2009026537		⤷ Sign Up
Russian Federation	2013101580	КРИСТАЛЛИЧЕСКАЯ ФОРМА БЕНЗИЛ-БЕНЗОЛЬНОГО ИНГИБИТОРА SGLT	⤷ Sign Up
Israel	203915	תולדות של 2-בנזילפניל-6-הידרוקסימתיל-טטראהידרו-2h-פירנ-3,4,5-טריאול ותכשירים רוקחיים המכילים אותן (2-benzylphenyl-6-hydroxymethyl-tetrahydro-2h-pyran-3,4,5-triol derivatives and pharmaceutical compositions comprising the same)	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.